The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in ...
GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA. The British drugmaker had been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results